Possibility/NN
of/IN
the/DT
Use/NN
of/IN
Public/JJ
Microarray/NN
Database/NN
for/IN
Identifying/NN
Significant/JJ
Genes/NNS
Associated/VBN
with/IN
Oral/JJ
Squamous/JJ
Cell/NN
Carcinoma/NN
./.
====================
There/EX
are/VBP
lots/NNS
of/IN
studies/NNS
attempting/VBG
to/TO
identify/VB
the/DT
expression/NN
changes/NNS
in/IN
oral/JJ
squamous/JJ
cell/NN
carcinoma/NN
./.
====================
Most/JJS
studies/NNS
include/VBP
insufficient/JJ
samples/NNS
to/TO
apply/RB
statistical/JJ
methods/NNS
for/IN
detecting/VBG
significant/JJ
gene/NN
sets/NNS
./.
====================
This/DT
study/NN
combined/VBD
two/CD
small/JJ
microarray/NN
datasets/NNS
from/IN
a/DT
public/JJ
database/NN
and/CC
identified/VBD
significant/JJ
genes/NNS
associated/VBN
with/IN
the/DT
progress/NN
of/IN
oral/JJ
squamous/JJ
cell/NN
carcinoma/NN
./.
====================
There/EX
were/VBD
different/JJ
expression/NN
scales/VBZ
between/IN
the/DT
two/CD
datasets/NNS
,/,
even/RB
though/IN
these/DT
datasets/NNS
were/VBD
generated/VBN
under/IN
the/DT
same/JJ
platforms/NNS
-/:
Affymetrix/JJ
U133A/NN
gene/NN
chips/NNS
./.
====================
We/PRP
discretized/VBD
gene/NN
expressions/NNS
of/IN
the/DT
two/CD
datasets/NNS
by/IN
adjusting/VBG
the/DT
differences/NNS
between/IN
the/DT
datasets/NNS
for/IN
detecting/VBG
the/DT
more/RBR
reliable/JJ
information/NN
./.
====================
From/IN
the/DT
combination/NN
of/IN
the/DT
two/CD
datasets/NNS
,/,
we/PRP
detected/VBD
51/CD
significant/JJ
genes/NNS
that/WDT
were/VBD
upregulated/VBN
in/IN
oral/JJ
squamous/JJ
cell/NN
carcinoma/NN
./.
====================
Most/JJS
of/IN
them/PRP
were/VBD
published/VBN
in/IN
previous/JJ
studies/NNS
as/IN
cancer-related/VBN
genes/NNS
./.
====================
From/IN
these/DT
selected/VBN
genes/NNS
,/,
significant/JJ
genetic/JJ
pathways/NNS
associated/VBN
with/IN
expression/NN
changes/NNS
were/VBD
identified/VBN
./.
====================
By/IN
combining/VBG
several/JJ
datasets/NNS
from/IN
the/DT
public/JJ
database/NN
,/,
sufficient/JJ
samples/NNS
can/MD
be/VB
obtained/VBN
for/IN
detecting/VBG
reliable/JJ
information/NN
./.
====================
Most/JJS
of/IN
the/DT
selected/VBN
genes/NNS
were/VBD
known/VBN
as/IN
cancer-related/VBN
genes/NNS
,/,
including/VBG
oral/JJ
squamous/JJ
cell/NN
carcinoma/NN
./.
====================
Several/JJ
unknown/JJ
genes/NNS
can/MD
be/VB
biologically/RB
evaluated/VBD
in/IN
further/JJ
studies/NNS
./.
====================
Despite/IN
recent/JJ
advances/NNS
in/IN
surgical/JJ
,/,
radiation/NN
,/,
and/CC
chemotherapeutic/JJ
treatment/NN
protocols/NNS
,/,
the/DT
prognosis/NN
of/IN
oral/JJ
squamous/JJ
cell/NN
carcinoma/NN
(/(
OSCC/NN
)/)
remains/VBZ
mournful/JJ
,/,
with/IN
an/DT
approximate/JJ
50/CD
%/NN
5-year/JJ
mortality/NN
rate/NN
from/IN
disease/NN
or/CC
associated/VBN
complications/NNS
[/(
1/CD
]/)
./.
====================
Therefore/RB
,/,
the/DT
identification/NN
of/IN
biological/JJ
markers/NNS
is/VBZ
essential/JJ
to/TO
make/VB
progress/VBP
in/IN
detecting/VBG
malignancy/NN
at/IN
an/DT
early/JJ
stage/NN
and/CC
developing/VBG
novel/JJ
therapies/NNS
[/(
2/CD
]/)
./.
====================
Microarray/NN
datasets/NNS
that/DT
are/VBP
created/VBN
for/IN
the/DT
same/JJ
research/NN
purposes/NNS
in/IN
different/JJ
laboratories/NNS
have/VBP
accumulated/VBN
rapidly/RB
./.
====================
The/DT
results/NNS
from/IN
different/JJ
datasets/NNS
are/VBP
often/RB
inconsistent/JJ
due/JJ
to/TO
the/DT
utilization/NN
of/IN
different/JJ
platforms/NNS
,/,
sample/NN
preparations/NNS
,/,
or/CC
various/JJ
technical/JJ
variations/NNS
./.
====================
If/IN
we/PRP
could/MD
combine/VB
such/JJ
datasets/NNS
by/IN
adjusting/VBG
for/IN
systematic/JJ
biases/NNS
that/DT
exist/VBP
among/IN
different/JJ
datasets/NNS
derived/VBN
from/IN
different/JJ
experimental/JJ
conditions/NNS
,/,
the/DT
power/JJ
of/IN
statistical/JJ
tests/NNS
would/MD
be/VB
improved/VBN
by/IN
the/DT
increase/NN
in/IN
sample/JJ
size/NN
[/(
3/CD
]/)
./.
====================
In/IN
OSCC/NN
,/,
although/IN
lots/NNS
of/IN
microarray-based/VBN
studies/NNS
have/VBP
been/VBN
conducted/VBN
to/TO
provide/VB
insights/NNS
into/IN
gene/NN
expression/NN
changes/NNS
,/,
most/JJS
of/IN
these/DT
studies/NNS
have/VBP
contained/VBN
insufficient/JJ
samples/NNS
for/IN
detecting/VBG
reliable/JJ
information/NN
using/VBG
statistical/JJ
analysis/NN
[/(
4/CD
,/,
5/CD
]/)
./.
====================
Therefore/RB
,/,
this/DT
study/NN
attempted/VBD
to/TO
combine/VB
several/JJ
datasets/NNS
in/IN
the/DT
public/JJ
database/NN
for/IN
detecting/VBG
significant/JJ
genes/NNS
./.
====================
We/PRP
used/VBD
two/CD
small/JJ
microarray/NN
datasets/NNS
of/IN
OSCC/NN
for/IN
this/DT
study/NN
,/,
which/WDT
were/VBD
based/VBN
on/IN
the/DT
same/JJ
platform/NN
but/CC
had/VBD
different/JJ
expression/NN
scales/VBZ
./.
====================
These/DT
two/CD
datasets/NNS
were/VBD
combined/VBN
after/IN
discretization/NN
,/,
because/IN
a/DT
previous/JJ
study/NN
showed/VBD
that/IN
classification/NN
could/MD
be/VB
improved/VBN
using/VBG
combined/JJ
datasets/NNS
after/IN
discretization/NN
[/(
3/CD
]/)
./.
====================
After/IN
combining/VBG
datasets/NNS
,/,
we/PRP
used/VBD
chi-square/NN
test/NN
for/IN
identifying/VBG
the/DT
significant/JJ
genes/NNS
./.
====================
Chi-square/JJ
test/NN
has/VBZ
been/VBN
used/VBN
commonly/RB
to/TO
detect/VB
differentially/RB
expressed/VBN
genes/NNS
after/IN
discretization/NN
of/IN
expression/NN
intensities/VBZ
in/IN
the/DT
microarray/NN
experiment/NN
./.
====================
In/IN
this/DT
study/NN
,/,
gene/NN
expression/NN
ratios/NNS
of/IN
two/CD
datasets/NNS
were/VBD
transformed/VBN
with/IN
their/PRP$
ranks/NNS
for/IN
each/DT
dataset/NN
./.
====================
Next/RB
,/,
the/DT
transformed/VBN
datasets/NNS
were/VBD
combined/VBN
,/,
and/CC
a/DT
nonparametric/JJ
statistical/JJ
method/NN
was/VBD
applied/VBN
to/TO
the/DT
combined/JJ
dataset/NN
to/TO
detect/VB
informative/JJ
genes/NNS
./.
====================
Finally/RB
,/,
we/PRP
showed/VBD
that/IN
most/JJS
of/IN
the/DT
selected/VBN
genes/NNS
were/VBD
known/VBN
to/TO
be/VB
involved/VBN
in/IN
various/JJ
cancers/NNS
,/,
including/VBG
OSCC/NN
./.
====================
Dataset/NN
====================
Two/CD
microarray/NN
datasets/NNS
were/VBD
used/VBN
for/IN
this/DT
study/NN
./.
====================
We/PRP
acquired/VBD
these/DT
datasets/NNS
from/IN
a/DT
public/JJ
database/NN
(/(
Gene/NN
Expression/NN
Omnibus/NN
,/,
GEO/NN
)/)
./.
====================
One/CD
was/VBD
the/DT
expression/NN
dataset/NN
of/IN
16/CD
tumors/NNS
and/CC
4/CD
normal/JJ
tissues/NNS
from/IN
16/CD
patients/NNS
,/,
using/VBG
Affymetrix/JJ
U133A/NN
gene/NN
chips/NNS
(/(
Affymetrix/JJ
,/,
Santa/NN
Clara/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
./.
====================
The/DT
other/JJ
microarray/NN
dataset/NN
consisted/VBD
of/IN
expression/NN
profiles/NNS
of/IN
22/CD
tumors/NNS
and/CC
5/CD
normal/JJ
tissues/NNS
./.
====================
These/DT
two/CD
datasets/NNS
were/VBD
experimented/VBN
on/IN
under/IN
the/DT
same/JJ
platform/NN
,/,
Affymetrix/JJ
U133A/NN
./.
====================
The/DT
datasets/NNS
are/VBP
summarized/VBN
in/IN
Table/JJ
1/CD
./.
====================
Process/NN
for/IN
combining/VBG
datasets/NNS
====================
For/IN
combining/VBG
datasets/NNS
,/,
gene/NN
expression/NN
ratios/NNS
are/VBP
rearranged/VBN
in/IN
order/NN
of/IN
expression/NN
ratios/NNS
by/IN
each/DT
gene/NN
in/IN
each/DT
dataset/NN
,/,
and/CC
the/DT
ranks/NNS
are/VBP
matched/VBN
with/IN
the/DT
corresponding/JJ
experimental/JJ
group/NN
./.
====================
If/IN
the/DT
experimental/JJ
groups/NNS
are/VBP
homogenous/JJ
,/,
the/DT
ranks/NNS
within/IN
the/DT
same/JJ
experimental/JJ
group/NN
would/MD
be/VB
neighboring/JJ
./.
====================
The/DT
process/NN
of/IN
discretization/NN
of/IN
gene/NN
expressions/NNS
is/VBZ
summarized/VBN
in/IN
the/DT
following/VBG
steps/NNS
[/(
3/CD
]/)
:/:
====================
Rank/NN
the/DT
gene/NN
expression/NN
ratios/NNS
within/IN
a/DT
gene/NN
for/IN
each/DT
dataset/NN
./.
====================
List/NN
in/IN
order/NN
of/IN
the/DT
ranks/NNS
,/,
and/CC
assign/NN
the/DT
order/NN
of/IN
gene/NN
expressions/NNS
to/TO
the/DT
corresponding/JJ
experimental/JJ
groups/NNS
./.
====================
Summarize/NN
the/DT
result/NN
of/IN
(/(
2/CD
)/)
in/IN
the/DT
form/NN
of/IN
a/DT
contingency/NN
table/JJ
for/IN
each/DT
gene/NN
./.
====================
Combine/NN
the/DT
contingency/NN
tables/NNS
that/DT
have/VBP
been/VBN
summarized/VBN
for/IN
each/DT
dataset/NN
./.
====================
When/WRB
there/EX
are/VBP
three/CD
datasets/NNS
to/TO
be/VB
combined/VBN
,/,
the/DT
datasets/NNS
can/MD
be/VB
added/VBN
as/IN
a/DT
single/JJ
entry/NN
,/,
as/IN
shown/VBN
in/IN
Table/JJ
2/CD
,/,
after/IN
the/DT
transformation/NN
of/IN
each/DT
dataset/NN
by/IN
rank/NN
./.
====================
Identification/NN
of/IN
significant/JJ
genes/NNS
from/IN
a/DT
combined/JJ
dataset/NN
====================
After/IN
the/DT
summarization/NN
of/IN
gene/NN
expression/NN
ratios/NNS
in/IN
the/DT
form/NN
of/IN
a/DT
contingency/NN
table/JJ
for/IN
each/DT
gene/NN
,/,
as/IN
shown/VBN
in/IN
Table/JJ
3/CD
,/,
a/DT
nonparametric/JJ
statistical/JJ
method/NN
was/VBD
applied/VBN
to/TO
the/DT
datasets/NNS
for/IN
independence/NN
testing/VBG
between/IN
gene/NN
expression/NN
patterns/NNS
and/CC
experimental/JJ
groups/NNS
./.
====================
The/DT
test/NN
statistics/NNS
are/VBP
calculated/VBN
as/IN
follows/VBZ
for/IN
each/DT
gene/NN
:/:
====================
When/WRB
the/DT
sample/NN
size/NN
is/VBZ
small/JJ
-/:
generally/RB
ÃŠ/NN
(/(
nij/CD
)/)
less/RBR
than/IN
5/CD
-/:
Fisher/DT
's/POS
exact/JJ
test/NN
is/VBZ
recommended/VBN
rather/RB
than/IN
chi-square/NN
test/NN
./.
====================
The/DT
significant/JJ
genes/NNS
can/MD
be/VB
selected/VBN
by/IN
an/DT
independence/NN
test/NN
between/IN
the/DT
phenotypes/NNS
and/CC
gene/NN
expressions/NNS
using/VBG
this/DT
type/NN
of/IN
summarized/VBN
dataset/NN
./.
====================
ci/NNS
and/CC
ri/NN
represent/VBP
the/DT
marginal/JJ
sums/NNS
of/IN
the/DT
ith/NN
column/NN
and/CC
row/NN
,/,
respectively/RB
./.
====================
nij/DT
is/VBZ
the/DT
number/NN
of/IN
experiments/NNS
belonging/VBG
to/TO
Ei/JJ
and/CC
Pj/NN
,/,
and/CC
n/NN
represents/VBZ
the/DT
total/JJ
number/NN
of/IN
experiments/NNS
./.
====================
The/DT
clinical/JJ
information/NN
and/CC
expression/NN
levels/NNS
of/IN
two/CD
datasets/NNS
are/VBP
summarized/VBN
in/IN
Table/JJ
4/CD
and/CC
Fig/NN
./.
====================
1/CD
./.
====================
Subgroup/NN
and/CC
sex/NN
were/VBD
similarly/RB
distributed/VBN
in/IN
the/DT
two/CD
datasets/NNS
./.
====================
The/DT
distributions/NNS
of/IN
other/JJ
factors/NNS
were/VBD
not/RB
included.The/DT
scale/NN
of/IN
expression/NN
levels/NNS
in/IN
the/DT
two/CD
datasets/NNS
was/VBD
different/JJ
;/:
the/DT
expression/NN
values/NNS
of/IN
Data/NNS
2004/CD
ranged/VBD
from/IN
0.01/CD
to/TO
740/CD
,/,
and/CC
those/DT
of/IN
Data/NNS
2005/CD
were/VBD
from/IN
0.1/CD
to/TO
19,773/CD
./.
====================
The/DT
expression/NN
patterns/NNS
of/IN
the/DT
two/CD
datasets/NNS
can/MD
be/VB
explored/VBN
in/IN
Fig/NN
./.
====================
1.Lots/NNS
of/IN
outliers/NNS
are/VBP
shown/VBN
in/IN
Fig/NN
./.
====================
1A/NN
in/IN
the/DT
two/CD
datasets/NNS
containing/VBG
whole/JJ
gene/NN
sets/NNS
./.
====================
However/RB
,/,
in/IN
subsets/NNS
of/IN
significant/JJ
genes/NNS
,/,
the/DT
expression/NN
ranges/VBZ
got/NN
narrow/JJ
,/,
and/CC
the/DT
outliers/NNS
were/VBD
decreased/VBN
(/(
Fig/NN
./.
====================
1B/NN
)/)
./.
====================
The/DT
expressions/NNS
of/IN
tumor/NN
tissues/NNS
in/IN
Data/NNS
2004/CD
were/VBD
upregulated/VBN
and/CC
varied/VBD
compared/VBN
with/IN
normal/JJ
tissues/NNS
./.
====================
If/IN
there/EX
was/VBD
no/DT
outlier/RB
with/IN
a/DT
maximum/JJ
value/NN
in/IN
the/DT
14th/JJ
tumor/NN
tissue/NN
in/IN
Data/NNS
2004/CD
,/,
the/DT
expressions/NNS
of/IN
the/DT
two/CD
different/JJ
groups/NNS
would/MD
be/VB
clearly/RB
distinguished/VBN
./.
====================
Any/DT
clear/JJ
differences/NNS
in/IN
expression/NN
were/VBD
not/RB
shown/VBN
between/IN
the/DT
two/CD
groups/NNS
in/IN
Data/NNS
2005/CD
./.
====================
Upregulated/JJ
51/CD
genes/NNS
in/IN
oral/JJ
squamous/JJ
cell/NN
carcinoma/NN
====================
To/TO
identify/VB
differently/RB
expressed/VBN
genes/NNS
between/IN
normal/JJ
and/CC
tumor/NN
tissues/NNS
,/,
we/PRP
performed/VBD
chi-square/NN
test/NN
using/VBG
a/DT
combined/JJ
microarray/NN
dataset/NN
./.
====================
Fifty-one/CD
significant/JJ
genes/NNS
were/VBD
selected/VBN
from/IN
a/DT
combined/JJ
dataset/NN
with/IN
p-value/JJ
less/RBR
than/IN
0.005/CD
,/,
which/WDT
were/VBD
upregulated/VBN
in/IN
OSCC/NN
tissues/NNS
./.
====================
The/DT
significance/NN
level/NN
can/MD
be/VB
controlled/VBN
,/,
and/CC
more/RBR
genes/NNS
can/MD
be/VB
selected/VBN
with/IN
a/DT
lower/JJR
significance/NN
level/NN
./.
====================
These/DT
selected/VBN
genes/NNS
are/VBP
summarized/VBN
in/IN
Table/JJ
5/CD
./.
====================
Many/JJ
genes/NNS
among/IN
the/DT
selected/VBN
genes/NNS
were/VBD
known/VBN
as/IN
cancer-related/VBN
genes/NNS
./.
====================
STAT1/NN
[/(
6/CD
]/)
,/,
SKP2/NN
[/(
7/CD
]/)
,/,
IFI16/NN
[/(
8/CD
]/)
,/,
RHEB/NN
[/(
9/CD
]/)
,/,
FIF44/NN
[/(
10/CD
]/)
,/,
SOD2/NN
[/(
11/CD
,/,
12/CD
]/)
,/,
and/CC
GREM1/NN
[/(
11/CD
]/)
are/VBP
related/JJ
to/TO
OSCC/NN
./.
====================
Table/JJ
6/CD
[/(
13-56/CD
]/)
summarizes/VBZ
the/DT
previous/JJ
studies/NNS
that/IN
have/VBP
published/VBN
the/DT
relations/NNS
of/IN
selected/VBN
genes/NNS
with/IN
cancer/NN
./.
====================
Expression/NN
pattern/NN
of/IN
the/DT
identified/VBN
genes/NNS
====================
To/TO
investigate/VB
whether/IN
the/DT
different/JJ
experimental/JJ
groups/NNS
could/MD
be/VB
classified/VBN
with/IN
significant/JJ
genes/NNS
,/,
an/DT
unsupervised/JJ
hierarchical/JJ
clustering/NN
method/NN
was/VBD
applied/VBN
to/TO
the/DT
significant/JJ
gene/NN
set/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
The/DT
normal/JJ
group/NN
consisted/VBD
of/IN
4/CD
tissues/NNS
and/CC
showed/VBD
significantly/RB
lower/JJR
expression/NN
levels/NNS
when/WRB
compared/VBN
with/IN
the/DT
tumor/NN
group/NN
./.
====================
In/IN
Fig/NN
./.
====================
2/CD
,/,
we/PRP
investigated/VBD
the/DT
classification/NN
availability/NN
of/IN
the/DT
identified/VBN
genes/NNS
in/IN
Data/NNS
2004/CD
,/,
not/RB
in/IN
a/DT
combined/JJ
dataset/NN
,/,
because/IN
the/DT
two/CD
datasets/NNS
have/VBP
different/JJ
expression/NN
scales/VBZ
./.
====================
Network/NN
analysis/NN
====================
Based/VBN
on/IN
all/DT
identified/VBD
genes/NNS
,/,
new/JJ
and/CC
expanded/VBN
pathway/NN
maps/VBZ
and/CC
connections/NNS
and/CC
specific/JJ
gene-gene/NN
interactions/NNS
were/VBD
inferred/VBN
,/,
functionally/RB
analyzed/VBD
,/,
and/CC
used/VBN
to/TO
build/JJ
on/IN
the/DT
existing/VBG
pathway/NN
using/VBG
the/DT
Ingenuity/NN
Pathway/NN
Analysis/NN
(/(
IPA/NN
)/)
knowledge/NN
base/NN
[/(
57/CD
]/)
./.
====================
To/TO
generate/VB
networks/NNS
in/IN
this/DT
work/NN
,/,
the/DT
knowledge/NN
base/NN
was/VBD
queried/VBN
for/IN
interactions/NNS
between/IN
the/DT
identified/VBN
genes/NNS
and/CC
all/DT
other/JJ
genes/NNS
stored/VBD
in/IN
the/DT
database/NN
./.
====================
Four/CD
networks/NNS
were/VBD
found/VBN
to/TO
be/VB
significant/JJ
in/IN
OSCC/NN
./.
====================
The/DT
network/NN
with/IN
the/DT
highest/JJS
score/RB
(/(
Network/NN
1/CD
,/,
score/RB
=/JJ
36/CD
)/)
was/VBD
generated/VBN
,/,
with/IN
17/CD
identified/VBD
genes/NNS
(/(
Table/JJ
7/CD
,/,
Fig/NN
./.
====================
3/CD
)/)
./.
====================
In/IN
the/DT
network/NN
diagram/NN
,/,
STAT1/NN
and/CC
SOD2/NN
neighbored/JJ
with/IN
NMI/NN
and/CC
AURKA/NN
,/,
respectively/RB
./.
====================
The/DT
expression/NN
levels/NNS
of/IN
STAT1/NN
and/CC
SOD2/NN
could/MD
be/VB
expected/VBN
to/TO
be/VB
related/JJ
with/IN
those/DT
of/IN
NMI/NN
and/CC
SOD2/NN
./.
====================
Actually/RB
,/,
the/DT
expressions/NNS
of/IN
STAT1/NN
and/CC
SOD2/NN
were/VBD
strongly/RB
positively/RB
correlated/VBD
with/IN
NMI/NN
(/(
r/NN
=/JJ
0.95/CD
)/)
and/CC
AURKA/NN
(/(
r/NN
=/JJ
0.87/CD
)/)
,/,
respectively/RB
./.
====================
OSCC/NN
is/VBZ
associated/VBN
with/IN
substantial/JJ
mortality/NN
and/CC
morbidity/NN
[/(
58/CD
]/)
./.
====================
To/TO
identify/VB
potential/JJ
biomarkers/NNS
for/IN
early/JJ
detection/NN
of/IN
invasive/JJ
OSCC/NN
,/,
microarray/NN
experiments/NNS
have/VBP
been/VBN
conducted/VBN
,/,
and/CC
these/DT
kinds/NNS
of/IN
microarray/NN
datasets/NNS
have/VBP
accumulated/VBN
rapidly/RB
in/IN
the/DT
public/JJ
database/NN
./.
====================
However/RB
,/,
there/EX
are/VBP
many/JJ
datasets/NNS
that/DT
include/VBP
insufficient/JJ
sample/NN
sizes/NNS
for/IN
detecting/VBG
significant/JJ
genes/NNS
by/IN
statistical/JJ
analysis/NN
./.
====================
Therefore/RB
,/,
this/DT
study/NN
attempted/VBD
to/TO
combine/VB
several/JJ
microarray/NN
datasets/NNS
from/IN
a/DT
public/JJ
database/NN
to/TO
identify/VB
significant/JJ
candidates/NNS
as/IN
biomarkers/NNS
./.
====================
In/IN
a/DT
microarray/NN
data/NNS
analysis/NN
,/,
the/DT
information/NN
from/IN
different/JJ
datasets/NNS
obtained/VBN
under/IN
different/JJ
experimental/JJ
conditions/NNS
may/MD
be/VB
inconsistent/JJ
even/RB
though/IN
they/PRP
are/VBP
performed/VBN
with/IN
the/DT
same/JJ
research/NN
objectives/VBZ
./.
====================
Moreover/RB
,/,
even/RB
when/WRB
the/DT
datasets/NNS
are/VBP
generated/VBN
by/IN
the/DT
same/JJ
platform/NN
,/,
the/DT
data/NNS
agreement/NN
may/MD
be/VB
affected/VBN
by/IN
technical/JJ
variations/NNS
between/IN
laboratories/NNS
./.
====================
In/IN
such/JJ
cases/NNS
,/,
it/PRP
could/MD
be/VB
necessary/JJ
to/TO
use/VB
a/DT
combined/JJ
dataset/NN
after/IN
adjusting/VBG
for/IN
the/DT
differences/NNS
between/IN
such/JJ
datasets/NNS
for/IN
detecting/VBG
the/DT
more/RBR
reliable/JJ
information/NN
./.
====================
Combining/VBG
datasets/NNS
is/VBZ
especially/RB
useful/JJ
in/IN
OSCC/NN
microarray/NN
datasets/NNS
,/,
because/IN
there/EX
are/VBP
many/JJ
datasets/NNS
with/IN
insufficient/JJ
sample/NN
sizes/NNS
for/IN
analysis/NN
[/(
4/CD
,/,
5/CD
,/,
59/CD
,/,
60/CD
]/)
./.
====================
For/IN
identifying/VBG
significant/JJ
genes/NNS
classifying/VBG
tumor/NN
and/CC
normal/JJ
groups/NNS
,/,
we/PRP
achieved/VBD
two/CD
microarray/NN
datasets/NNS
from/IN
a/DT
public/JJ
database/NN
,/,
GEO/NN
./.
====================
They/PRP
included/VBD
20/CD
and/CC
27/CD
samples/NNS
,/,
and/CC
each/DT
sample/NN
size/NN
was/VBD
unbalanced/JJ
between/IN
the/DT
different/JJ
groups/NNS
./.
====================
By/IN
combining/VBG
these/DT
two/CD
datasets/NNS
,/,
the/DT
sample/NN
size/NN
was/VBD
increased/VBN
,/,
and/CC
we/PRP
had/VBD
a/DT
sufficient/JJ
sample/NN
size/NN
for/IN
statistical/JJ
analysis/NN
,/,
even/RB
though/IN
it/PRP
was/VBD
still/RB
unbalanced/JJ
./.
====================
When/WRB
these/DT
datasets/NNS
were/VBD
combined/VBN
,/,
we/PRP
used/VBD
the/DT
rank/NN
of/IN
gene/NN
expression/NN
,/,
because/IN
the/DT
scale/NN
of/IN
gene/NN
expression/NN
was/VBD
different/JJ
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
identified/VBD
51/CD
significant/JJ
genes/NNS
from/IN
a/DT
combined/JJ
dataset/NN
,/,
and/CC
this/DT
number/NN
could/MD
be/VB
increased/VBN
or/CC
decreased/VBD
by/IN
the/DT
significance/NN
level/NN
(/(
we/PRP
used/VBD
0.005/CD
)/)
./.
====================
The/DT
selected/VBN
51/CD
genes/NNS
were/VBD
upregulated/VBN
in/IN
tumor/NN
tissues/NNS
./.
====================
Many/JJ
of/IN
the/DT
selected/VBN
genes/NNS
were/VBD
proven/VBN
to/TO
be/VB
cancer-related/VBN
genes/NNS
by/IN
previous/JJ
studies/NNS
./.
====================
SOD2/NN
is/VBZ
associated/VBN
with/IN
lymph/NN
node/NN
metastasis/NN
in/IN
OSCC/NN
and/CC
may/MD
provide/VB
predictive/JJ
values/NNS
for/IN
the/DT
diagnosis/NN
of/IN
metastasis/NN
[/(
10/CD
]/)
./.
====================
Metastasis/NN
is/VBZ
a/DT
critical/JJ
event/NN
in/IN
OSCC/NN
progression/NN
./.
====================
An/DT
SOD2/NN
variant/JJ
has/VBZ
also/RB
been/VBN
associated/VBN
with/IN
increased/VBN
breast/NN
cancer/NN
and/CC
ovarian/JJ
cancer/NN
risk/NN
in/IN
previous/JJ
studies/NNS
[/(
47/CD
,/,
61/CD
]/)
./.
====================
TopBP1/NN
included/VBD
eight/CD
BRCT/NN
domains/NNS
(/(
originally/RB
identified/VBN
in/IN
BRCA1/NN
)/)
,/,
and/CC
it/PRP
was/VBD
proposed/VBN
as/IN
a/DT
breast/NN
cancer/NN
susceptibility/NN
gene/NN
[/(
18/CD
,/,
62/CD
]/)
./.
====================
By/IN
semiquantitative/JJ
reverse/JJ
transcription/NN
PCR/NN
analysis/NN
,/,
RHEB/NN
was/VBD
shown/VBN
to/TO
be/VB
upregulated/VBN
in/IN
OSCC/NN
[/(
9/CD
]/)
./.
====================
In/IN
salivary/JJ
cancer/NN
,/,
survival/NN
probability/NN
rates/NNS
dropped/VBD
when/WRB
Skp2/NN
was/VBD
overexpressed/VBN
[/(
7/CD
]/)
./.
====================
Overexpression/NN
of/IN
Skp2/NN
is/VBZ
associated/VBN
with/IN
the/DT
reduction/NN
of/IN
p27/NN
(/(
KIP1/NN
)/)
expression/NN
and/CC
may/MD
have/VB
a/DT
role/NN
in/IN
the/DT
progression/NN
of/IN
OSCC/NN
[/(
25/CD
]/)
./.
====================
The/DT
expression/NN
of/IN
RCN2/NN
was/VBD
linearly/RB
related/JJ
to/TO
the/DT
tumor/NN
mass/NN
increase/VBP
,/,
and/CC
its/PRP$
expression/NN
was/VBD
increased/VBN
in/IN
breast/NN
cancer/NN
[/(
16/CD
]/)
./.
====================
PTPRK/NN
was/VBD
proven/VBN
as/IN
a/DT
candidate/NN
gene/NN
of/IN
colorectal/JJ
cancer/NN
[/(
19/CD
]/)
,/,
and/CC
it/PRP
is/VBZ
a/DT
functional/JJ
tumor/NN
suppressor/NN
in/IN
Hodgkin/NN
lymphoma/NN
cells/NNS
[/(
20/CD
]/)
./.
====================
DMTF1/NN
was/VBD
shown/VBN
to/TO
be/VB
amplified/VBN
in/IN
adenocarcinoma/NN
of/IN
the/DT
gastroesophageal/JJ
junction/NN
,/,
residing/VBG
at/IN
7q21/NN
by/IN
aCGH/JJ
experiments/NNS
[/(
21/CD
]/)
./.
====================
FEZ1/NN
was/VBD
involved/VBN
in/IN
ovarian/JJ
carcinogenesis/NN
,/,
and/CC
its/PRP$
reduction/NN
or/CC
loss/NN
could/MD
be/VB
an/DT
aid/NN
to/TO
the/DT
clinical/JJ
management/NN
of/IN
patients/NNS
affected/VBD
by/IN
ovarian/JJ
carcinoma/NN
[/(
22/CD
]/)
./.
====================
It/PRP
is/VBZ
also/RB
a/DT
known/JJ
tumor/NN
suppressor/NN
gene/NN
in/IN
breast/NN
cancer/NN
and/CC
gastric/JJ
cancer/NN
[/(
23/CD
,/,
63/CD
]/)
./.
====================
Other/JJ
ovarian/JJ
cancer-related/JJ
genes/NNS
were/VBD
NMI/NN
[/(
27/CD
,/,
28/CD
]/)
and/CC
FANCI/NN
[/(
44/CD
]/)
;/:
breast/NN
cancer-related/JJ
genes/NNS
were/VBD
COX11/NN
[/(
42/CD
]/)
,/,
MELK/NN
[/(
33/CD
]/)
,/,
and/CC
FANCI/NN
[/(
44/CD
]/)
among/IN
the/DT
selected/VBN
genes/NNS
./.
====================
MELK/NN
was/VBD
known/VBN
to/TO
be/VB
associated/VBN
with/IN
shorter/JJR
survival/NN
in/IN
glioblastoma/NN
[/(
34/CD
]/)
./.
====================
TTK/NN
was/VBD
associated/VBN
with/IN
progression/NN
and/CC
metastasis/NN
of/IN
advanced/JJ
cervical/JJ
cancers/NNS
after/IN
radiotherapy/NN
[/(
29/CD
,/,
30/CD
]/)
./.
====================
It/PRP
might/MD
also/RB
be/VB
a/DT
relevant/JJ
candidate/NN
as/IN
a/DT
new/JJ
target/NN
in/IN
cancer/NN
therapy/NN
,/,
since/IN
it/PRP
plays/VBZ
relevant/JJ
roles/NNS
in/IN
mitotic/JJ
progression/NN
and/CC
the/DT
spindle/NN
checkpoint/NN
[/(
31/CD
,/,
32/CD
]/)
./.
====================
Aurora/NN
kinase/NN
A/NN
(/(
AURKA/NN
)/)
was/VBD
associated/VBN
with/IN
skin/NN
tumors/NNS
[/(
36/CD
]/)
and/CC
colorectal/JJ
cancer/NN
[/(
37/CD
,/,
38/CD
]/)
./.
====================
In/IN
previous/JJ
studies/NNS
,/,
OSCC-related/JJ
genes/NNS
among/IN
the/DT
selected/VBN
genes/NNS
were/VBD
STAT1/NN
[/(
14/CD
]/)
,/,
SKP2/NN
[/(
7/CD
,/,
25/CD
]/)
,/,
IFI16/NN
[/(
8/CD
]/)
,/,
RHEB/NN
[/(
9/CD
]/)
,/,
IFI44/NN
[/(
64/CD
]/)
,/,
SOD2/NN
[/(
10-12/CD
]/)
,/,
and/CC
GREM1/NN
[/(
11/CD
]/)
./.
====================
The/DT
gene/NN
set/NN
,/,
which/WDT
has/VBZ
not/RB
been/VBN
proven/VBN
as/IN
OSCC-related/JJ
genes/NNS
until/IN
now/RB
,/,
could/MD
be/VB
expected/VBN
to/TO
be/VB
possibly/RB
proven/VBN
as/IN
OSCC-related/JJ
genes/NNS
by/IN
biological/JJ
evaluation/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
identified/VBD
significant/JJ
genes/NNS
related/JJ
with/IN
OSCC/NN
from/IN
two/CD
microarray/NN
datasets/NNS
in/IN
a/DT
public/JJ
database/NN
./.
====================
For/IN
this/DT
,/,
we/PRP
transformed/VBD
microarray/NN
datasets/NNS
using/VBG
ranks/VBZ
of/IN
gene/NN
expressions/NNS
with/IN
different/JJ
expression/NN
scales/VBZ
,/,
even/RB
though/IN
they/PRP
were/VBD
constructed/VBN
under/IN
the/DT
same/JJ
experimental/JJ
conditions/NNS
./.
====================
This/DT
method/NN
could/MD
be/VB
useful/JJ
when/WRB
using/VBG
multiple/JJ
datasets/NNS
that/DT
are/VBP
created/VBN
for/IN
the/DT
same/JJ
research/NN
purpose/NN
,/,
By/IN
combining/VBG
these/DT
accumulated/VBN
datasets/NNS
,/,
we/PRP
can/MD
detect/VB
more/RBR
reliable/JJ
information/NN
due/IN
to/TO
the/DT
increased/VBN
sample/NN
size/NN
./.
====================
It/PRP
saves/VBZ
time/NN
and/CC
money/NN
and/CC
avoids/NNS
repeating/VBG
experiments/NNS
./.
====================
Comparison/NN
of/IN
expression/NN
levels/NNS
of/IN
two/CD
datasets/NNS
./.
====================
(/(
A/NN
)/)
Whole/NN
gene/NN
set/NN
./.
====================
(/(
B/NN
)/)
Selected/JJ
gene/NN
set/NN
./.
====================
Expression/NN
patterns/NNS
of/IN
the/DT
selected/VBN
51/CD
genes/NNS
./.
====================
These/DT
genes/NNS
were/VBD
upregulated/VBN
in/IN
oral/JJ
squamous/JJ
cell/NN
carcinoma/NN
tissues/NNS
,/,
and/CC
normal/JJ
and/CC
tumor/NN
groups/NNS
were/VBD
clearly/RB
classified/VBN
with/IN
these/DT
genes/NNS
./.
====================
Network/NN
with/IN
the/DT
highest/JJS
score/RB
(/(
Network/NN
1/CD
)/)
./.
====================
Functional/JJ
relationships/NNS
between/IN
genes/NNS
based/VBN
on/IN
known/VBN
interactions/NNS
in/IN
Ingenuity/NN
Pathway/NN
Analysis/NN
(/(
IPA/NN
)/)
knowledge/NN
are/VBP
described/VBN
./.
====================
Summary/JJ
of/IN
two/CD
microarray/NN
datasets/NNS
from/IN
GEO/NN
and/CC
the/DT
combined/JJ
dataset/NN
====================
Combination/NN
of/IN
contingency/NN
tables/NNS
for/IN
three/CD
datasets/NNS
(/(
tij/JJ
=/JJ
aij/NN
+/JJ
bij/NN
+/JJ
cij/NN
)/)
====================
Summary/JJ
of/IN
discretized/VBN
data/NNS
using/VBG
ranks/VBZ
of/IN
gene/NN
expressions/NNS
====================
Summary/JJ
of/IN
two/CD
microarray/NN
datasets/NNS
====================
Summary/JJ
of/IN
selected/VBN
51/CD
upregulated/VBN
genes/NNS
====================
Association/NN
of/IN
the/DT
selected/VBN
genes/NNS
and/CC
cancer/NN
====================
Four/CD
networks/NNS
generated/VBN
by/IN
upregulated/VBN
genes/NNS
in/IN
OSCC/NN
====================
